These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8369102)

  • 21. Long-term Levodopa Treatment Accelerates the Circadian Rhythm Dysfunction in a 6-hydroxydopamine Rat Model of Parkinson's Disease.
    Li SY; Wang YL; Liu WW; Lyu DJ; Wang F; Mao CJ; Yang YP; Hu LF; Liu CF
    Chin Med J (Engl); 2017 May; 130(9):1085-1092. PubMed ID: 28469105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
    Fernández Pardal MM; Gatto E; Micheli F; Casas Parera I; Diaz S
    Medicina (B Aires); 1991; 51(6):561-7. PubMed ID: 7476112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Lees AJ; Tolosa E; Olanow CW
    Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is the decreasing responsiveness of axial motor symptoms to L-dopa in elderly parkinsonian patients related to age-associated nonparkinsonian pathologies?
    Ransmayr G; Künig G; Neubauer M; Wagner M; Bösch S; Kreczy-Kleedorfer B
    Adv Neurol; 1993; 60():685-9. PubMed ID: 8420211
    [No Abstract]   [Full Text] [Related]  

  • 25. Endogenous melatonin protects L-DOPA from autoxidation in the striatal extracellular compartment of the freely moving rat: potential implication for long-term L-DOPA therapy in Parkinson's disease.
    Rocchitta G; Migheli R; Esposito G; Marchetti B; Desole MS; Miele E; Serra PA
    J Pineal Res; 2006 Apr; 40(3):204-13. PubMed ID: 16499555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
    J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3H-spiperone binding to lymphocytes fails in the differential diagnosis of de novo Parkinson syndromes.
    Arnold G; Bondy B; Bandmann O; Gasser T; Schwarz J; Trenkwalder C; Wagner M; Poewe W; Oertel WH
    J Neural Transm Park Dis Dement Sect; 1993; 5(2):107-16. PubMed ID: 7687443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease.
    Lees AJ
    Eur Neurol; 1987; 27 Suppl 1():126-34. PubMed ID: 3428306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Managing Parkinson's disease with continuous dopaminergic stimulation.
    Wolters E; Lees AJ; Volkmann J; van Laar T; Hovestadt A
    CNS Spectr; 2008 Apr; 13(4 Suppl 7):1-14; quiz 15-6. PubMed ID: 18408654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circadian effects of dopaminergic treatment in restless legs syndrome.
    Garcia-Borreguero D; Serrano C; Larrosa O; Granizo JJ
    Sleep Med; 2004 Jul; 5(4):413-20. PubMed ID: 15223002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The accelerated aging hypothesis of Parkinson's disease is not supported by the pattern of circadian melatonin secretion.
    Sandyk R
    Int J Neurosci; 1997 Aug; 90(3-4):271-5. PubMed ID: 9352432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. L-dopa and the secretion of sebum in Parkinsonian patients.
    Streifler M; Avrami E; Rabey JM
    Eur Neurol; 1980; 19(1):43-8. PubMed ID: 7371653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism.
    Naskar A; Manivasagam T; Chakraborty J; Singh R; Thomas B; Dhanasekaran M; Mohanakumar KP
    J Pineal Res; 2013 Oct; 55(3):304-12. PubMed ID: 23952687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diurnal motor variations to repeated doses of levodopa in Parkinson's disease.
    Bonuccelli U; Del Dotto P; Lucetti C; Petrozzi L; Bernardini S; Gambaccini G; Rossi G; Piccini P
    Clin Neuropharmacol; 2000; 23(1):28-33. PubMed ID: 10682228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of simulated hypo- and hyper-reproductive conditions on the characteristics of circadian rhythm in hypothalamic concentration of serotonin and dopamine and in plasma levels of thyroxine, triiodothyronine, and testosterone in Japanese quail, Coturnix coturnix japonica.
    Kumar P; Pati AK; Mohan J; Sastry KV; Tyagi JS; Chaturvedi CM
    Chronobiol Int; 2009 Jan; 26(1):28-46. PubMed ID: 19142756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypotensive effect of long-term levodopa in patients with Parkinson's disease.
    Iwasaki S; Hamaguchi K; Iwasaki A; Takakusagi M; Narabayashi Y
    Eur Neurol; 1990; 30(4):194-9. PubMed ID: 2209672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between tardive dyskinesia, L-Dopa-induced hyperkinesia and parkinsonism.
    Gerlach J
    Psychopharmacology (Berl); 1977 Mar; 51(3):259-63. PubMed ID: 403541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimum symptomatic control of Parkinson's disease with dopaminergic therapy.
    Bouchard S
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):460-5. PubMed ID: 3676921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The L-dopa test in Parkinson's disease].
    Esteguy M; Bonnet AM; Kefalos J; Lhermitte F; Agid Y
    Rev Neurol (Paris); 1985; 141(5):413-5. PubMed ID: 4048732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease.
    Del Dotto P; Colzi A; Musatti E; Strolin Benedetti M; Persiani S; Fariello R; Bonuccelli U
    Clin Neuropharmacol; 1997 Oct; 20(5):455-65. PubMed ID: 9331523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.